Epidemiology, Staging, and Management of Multiple Myeloma
Open accessThe DOI matches its Crossref record; 55 of the 56 references it cites were found in a registry or an index; 21 of the 61 sources its claims cite were checked for support.
Abstract
Multiple myeloma (MM) is a plasma cell disorder that is on the rise throughout the world, especially in the US, Australia, and Western Europe. In the US, MM accounts for almost 2% of cancer diagnoses and over 2% of cancer deaths (more than double the global proportion). Incidence has risen by 126% globally and over 40% in the US since 1990, while global mortality has risen by 94% and US mortality has fallen by 18%. The 5 year survival in the US has more than doubled over the past decades with the introduction of new targeted therapies and transplant techniques. Risk factors for MM include age (average age of diagnosis is 69), race (African Americans are over double as likely to be diagnosed), sex (men are at a 1.5× risk), and family history. Diagnosis includes serum or urine electrophoresis and free light-chain assay but requires bone marrow biopsy. It is distinguished from smoldering myeloma and monoclonal gammopathy of undetermined significance by a high (>3 g/dL) level of M-protein (monoclonal light chains) and the presence of CRAB (Hypercalcemia, Renal failure, Anemia, Bone pain) symptoms, which include hypercalcemia, renal failure, anemia, and bone pain, suggesting an end-organ damage. International staging system staging involves beta 2 microglobulin and albumin levels, while the revised system considers prognostic factors such as lactate dehydrogenase levels and chromosomal abnormalities. Front-line management includes induction regimen, maintenance therapy and hematopoietic cell transplantation for eligible patients and bisphosphonates or bone-stimulating agents for the prevention of skeletal events. Treatment for relapsed disease includes newly approved monoclonal antibodies like the CD38-targeting daratumumab, proteasome inhibitors, immunomodulating agents, and investigational therapies such as B cell maturation antigen Chimeric antigen receptor T cells.
Overview
CoChat Summary
## TL;DR
This 2021 review summarizes the epidemiology, staging, diagnosis, and management of multiple myeloma, emphasizing that incidence has risen while survival has improved with newer therapies and transplant techniques. It also highlights the major risk groups, current staging systems, and common first-line and relapsed-disease treatment approaches.
## Key findings
- Global MM burden was estimated at 160,000 cases in 2018 and 106,000 deaths in 2018; MM accounted for 0.9% of all cancer diagnoses and 1.1% of all cancer deaths.
- From 1990 to 2016, global incidence increased by 126% and global deaths increased by 94%; in the US, incidence rose by 143% since 1975, while mortality fell and 5-year survival increased from 23.7% in 1976 to 53.9% in 2016.
- Risk is higher in older adults (median diagnosis age 69 in the US), men (about 1.5× higher risk globally), and African Americans (incidence 16.5/100,000 in African American men and 12.0/100,000 in African American women, versus 8.2 and 5.0 in Caucasians).
- In an international clinical trial with 3,060 participants, 5-year survival by revised ISS stage was 82% for stage I, 62% for stage II, and 40% for stage III.
## Methods
- Narrative review article describing the “latest review” of MM; the paper states that an extensive literature search was done.
- Synthesizes epidemiologic data (e.g., GLOBOCAN, SEER), staging systems (ISS, DSS, revised ISS), diagnostic criteria, and treatment evidence from cited trials and studies.
- Main analysis is descriptive and integrative rather than experimental, comparing published incidence, mortality, risk-factor, staging, and treatment results.
## Limitations
- The paper does not report a systematic review method, search strategy, or inclusion/exclusion criteria; this is evident from the text (descriptive review), not stated as a limitation by the authors.
- The evidence base is largely observational and from cited studies/trials across different settings, so direct causal inference is limited; this is evident from the text.
- Not stated in the paper.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Map showing the estimated age-standardized incidence rates per 100,000 (world) in 2018 of multiple myeloma (MM) for both sexes and all ages. Created with mapchart.net. Data obtained from GLOBOCAN 2018 [7].](https://figures.cochat.ai/paper-figures/53cda705514b4aeea933ce5143d2fbf3/epidemiology-staging-and-management-of-multiple-myeloma-figure-1.jpg)
![Figure 2 Map showing the estimated age-standardized mortality rates per 100,000 (world) in 2018 of multiple myeloma for both sexes and all ages. Created with mapchart.net. Data obtained from GLOBOCAN 2018 [7].](https://figures.cochat.ai/paper-figures/0a44533b89b8450397215c10f72e1fcc/epidemiology-staging-and-management-of-multiple-myeloma-figure-2.jpg)
![Figure 3 Graph showing the estimated cumulative risk of incidence in 2018 of multiple myeloma for both sexes, ages 0–74. Created with Tableau 2019.2. Data obtained from GLOBOCAN 2018 [7].](https://figures.cochat.ai/paper-figures/525138bbaf0842a7aaa427b870ecd122/epidemiology-staging-and-management-of-multiple-myeloma-figure-3.jpg)
![Figure 4 Graph showing the estimated number of prevalent cases (5 year) as a population in 2018 of multiple myeloma for both sexes, ages 0–74. Created with Tableau 2019.2 Data obtained from GLOBOCAN 2018 [7].](https://figures.cochat.ai/paper-figures/6e96994452ec4de28c61f038e43ff651/epidemiology-staging-and-management-of-multiple-myeloma-figure-4.jpg)
![Figure 5 Bar chart showing the 5 year age-adjusted mortality rates from 2013–2017 by age for the United States. Created with Tableau 2019.2. Data source: SEER*Explorer [11].](https://figures.cochat.ai/paper-figures/82c4eb6e362047998968d2004b611456/epidemiology-staging-and-management-of-multiple-myeloma-figure-5.jpg)
![Figure 6 Bar chart showing the United States’ 5-year age-adjusted mortality rates from 2013–2017 for all races (including Hispanics). Created with Tableau 2019.2. Data source: SEER*Explorer [11].](https://figures.cochat.ai/paper-figures/b8ccac5b620b49deb4385d0716c909bd/epidemiology-staging-and-management-of-multiple-myeloma-figure-6.jpg)

Verification
Claims the paper makes
15 Valid · 12 Not valid · 29 Not checked · 10 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“KRd instead of VRd can be used as initial therapy in patients with t(4;14), t(14;16), t(14;20), and those with ≥2 high-risk abnormalities based on the results of phase 2 studies suggesting higher complete response (CR) rates and minimal residual disease negativity rates compared with historical results using VRd [28,30,31].”
§ Epidemiology, Staging, and Management of Multiple Myeloma > 3. Diagnosis, Staging, and Grading > 3.3. Management
What the sources say
- Disputedcites [28] Rajkumar, 2011, Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management, Am. J. Hematol. sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 0 partially supported, 1 disputed, 0 misattributed, 1 unverifiable. Expand the claim to see per-atom verdicts.
Checked by a reasoning model — may be wrong.
- Not checked yetcites [30] Rajkumar, 2010, Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management, Am. J. Hematol. source
Checked before — its earlier verdict is held back until a new check runs.
- Not checked — no full text of the sourcecites [31] Sheng, 2017, Carfilzomib-containing combinations as frontline therapy for multiple myeloma: A meta-analysis of 13 trials, Eur. J. Haematol. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Suggested underlying factors include discrepancies in health-risk behaviors, such as smoking and alcohol consumption, and higher rates of obesity among men, though none of these risk factors have been proven in MM [9].”
§ Epidemiology, Staging, and Management of Multiple Myeloma > 2. Epidemiology > 2.3. Risk Factors
What the sources say
- Partly supportedcites [9] Cowan, 2018, Global Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study 2016, JAMA Oncol. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says there is a “lack of known strong risk factors for myeloma,” which supports the claim’s general caution. It does not assess smoking, alcohol consumption, or obesity individually, or identify them as explanations for higher rates among men. (LLM, conf=0.82)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The revised international staging system (RISS) combines elements of tumor burden (ISS) and disease biology [23].”
§ Epidemiology, Staging, and Management of Multiple Myeloma > 3. Diagnosis, Staging, and Grading > 3.2. Staging
What the sources say
- Supportedcites [23] Palumbo, 2015, Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group, J. Clin. Oncol. source
The Introduction describes an ISS marker as reflecting tumour mass and identifies chromosomal abnormalities as biological features of multiple myeloma. The Discussion states that R-ISS combines ISS staging, chromosomal abnormalities and serum LDH, supporting the paraphrase. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Those undergoing HCT typically receive a triplet regimen for 3–4 months prior to stem cell collection in order to reduce tumor cell numbers in the bone marrow.”
§ Epidemiology, Staging, and Management of Multiple Myeloma > 3. Diagnosis, Staging, and Grading > 3.3. Management
What the sources say
- Could not verifycites [33] Chim, 2018, Management of relapsed and refractory multiple myeloma: Novel agents, antibodies, immunotherapies and beyond, Leukemia sourceExperimental — accuracy not yet measured
The 'Role of salvage ASCT' section discusses re-induction before a second transplant, and the 'Proposed treatment algorithm' section prefers triplets for relapsed myeloma. Neither addresses a typical 3–4-month triplet regimen before stem-cell collection to reduce tumor cells in the bone marrow; searches for that timing and purpose found no supporting passage. Page numbers were unavailable in our copy. (LLM, conf=0.76)
- Partly supportedcites [34] Laubach, 2016, Management of relapsed multiple myeloma: Recommendations of the International Myeloma Working Group, Leukemia sourceExperimental — accuracy not yet measured
Our copy supports the general idea that transplant-bound relapsed patients are treated with multi-drug regimens before harvest: 'General management' states that patients with high-risk/aggressive disease 'are generally treated with highly active three-or four-drug combinations to achieve maximal response' and that responders 'can then be considered for ASCT', and 'AUTOLOGOUS STEM CELL TRANSPLANTATION' notes that 'mobilization after reinduction using various mobilization regimen... is feasible' when a new stem cell collection is needed. However, no passage in our copy specifies a 3-4 month duration of pre-harvest therapy, nor does it state that the purpose of giving it before collection is to reduce tumour cell numbers in the bone marrow; the paper frames the three-drug approach as achieving maximal response in high-risk disease and explicitly leaves one- versus two- versus three-drug choice unsettled for indolent relapse. The quantitative and rationale components of the claim are therefore not attributable to this source. (LLM, conf=0.68)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Low-dose dexamethasone (i.e., once weekly 40 mg dose) is associated with less dexamethasone-related toxicity than more intensive dosing scheme without compromising efficacy [48].”
§ Epidemiology, Staging, and Management of Multiple Myeloma > 3. Diagnosis, Staging, and Grading > 3.3. Management
What the sources say
- Partly supportedcites [48] Rajkumar, 2010, Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: An open-label randomised controlled trial, Lancet Oncol. sourceExperimental — accuracy not yet measured
The Methods (Procedures; page unavailable) specify 40 mg dexamethasone once weekly in the low-dose arm. The Results and Discussion report less toxicity and no worse progression or survival outcomes with low-dose treatment, but the Results also find a significantly lower response rate after four cycles (68.3% versus 79%). Thus, “without compromising efficacy” is too broad, and the evidence is limited to treatment with lenalidomide in newly diagnosed myeloma. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
15 more claims · 1 with their cited sources checked
Create a free account to see all 66 claims and to verify the 18 references still open.
- Probably not a substantial claim. 27
- It may state two separate claims as one. 30
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Multiple myeloma affects men more than women (3:2 ratio). 5,6”
From Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. (2024) · cites this paper as [5]
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
Rajkumar, S. V., Dimopoulos, M. A., Palumbo, A., Blade, J., Merlini, G., Mateos, M.-V., Kumar, S., Hillengass, J., Kastritis, E., Richardson, P., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70442-5 · Cited by 4,978 · cited 3×
“5 mg/L, and Stage II for all those in between [19].”
BackgroundInternational Staging System for Multiple Myeloma
Greipp, P. R., Miguel, J. S., Durie, B. G. M., Crowley, J. J., Barlogie, B., Bladé, J., Boccadoro, M., Child, J. A., Avet-Loiseau, H., Kyle, R. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.242 · Cited by 2,974
Palumbo, A., Avet-Loiseau, H., Oliva, S., Lokhorst, H. M., Goldschmidt, H., Rosinol, L., Richardson, P., Caltagirone, S., Lahuerta, J. J., Facon, T., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.2267 · Cited by 2,210 · cited 1×
“The revised international staging system (RISS) combines elements of tumor burden (ISS) and disease biology [23].”
MethodBortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., Samoilova, O. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801479 · Cited by 1,899 · cited 1×
“Albeit weak, there is data suggesting that use of a proteasome inhibitor may abrogate the prognostic impact of at least some of these high-risk genetic markers [32].”
BackgroundDaratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Palumbo, A., Chanan-Khan, A., Weisel, K., Nooka, A. K., Masszi, T., Beksac, M., Spicka, I., Hungria, V., Munder, M., Mateos, M. V., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606038 · Cited by 1,522
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Dimopoulos, M. A., Oriol, A., Nahi, H., San-Miguel, J., Bahlis, N. J., Usmani, S. Z., Rabin, N., Orlowski, R. Z., Komarnicki, M., Suzuki, K., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607751 · Cited by 1,445 · cited 1×
“The recently approved monoclonal antibody, daratumumab, which targets CD38 (a re ceptor highly expr sed on myeloma cells), has become a favorite for later line induction regimens [35,36].”
BackgroundRajkumar, S. V., Jacobus, S., Callander, N. S., Fonseca, R., Vesole, D. H., Williams, M. E., Abonour, R., Siegel, D. S., Katz, M., & Greipp, P. R. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70284-0 · Cited by 933 · cited 1×
“, once weekly 40 mg dose) is associated with less dexamethasone-related toxicity than more intensive dosing scheme without compromising efficacy [48].”
BackgroundMoreau, P., Pylypenko, H., Grosicki, S., Karamanesht, I., Leleu, X., Grishunina, M., Rekhtman, G., Masliak, Z., Robak, T., Shubina, A., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70081-x · Cited by 920
Durie, B. G. M., Hoering, A., Abidi, M. H., Rajkumar, S. V., Epstein, J., Kahanic, S. P., Thakuri, M., Reu, F., Reynolds, C. M., Sexton, R., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31594-x · Cited by 908 · cited 1×
“, bortezomib, lenalidomide, dexamethasone) improved response rates, depth of response, progression-free survival, and overall survival compared with the then approved front-line regimen Rd (lenalidomide, dexamethasone) making a three-drug regimen the main stay of initial therapy for most patients with MM [25].”
Background
Research works printed but not linked: 3
- Howlander, N., Noone, A.M., Krapcho, M., Miller, D., Brest, A., Yu, M., Ruhl, J., Tatalovich, Z., Mariotto, A., and Lewis, D.R. (2019). SEER Cancer Statistics Review 1975–2016.
- Vakiti, A., Padala, S.A., and Mewawalla, P. (2020, May 07). Myeloma Kidney, Available online: https://www.ncbi.nlm.nih.gov/books/NBK499952/.
- Vakiti, A., and Mewawalla, P. (2020, May 07). Malignancy-Related Hypercalcemia, Available online: https://www.ncbi.nlm.nih.gov/books/NBK482423/.
Cited by
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Sonneveld, P., Dimopoulos, M. A., Boccadoro, M., Quach, H., Ho, P. J., Beksac, M., Hulin, C., Antonioli, E., Leleu, X., Mangiacavalli, S., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2312054 · Cited by 599
Malard, F., Neri, P., Bahlis, N. J., Terpos, E., Moukalled, N., Hungria, V. T. M., Manier, S., & Mohty, M. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00529-7 · Cited by 337
Huang, J., Chan, S. C., Lok, V., Zhang, L., Lucero-Prisno, D. E., Xu, W., Zheng, Z.-J., Elcarte, E., Withers, M., & Wong, M. C. S. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00165-x · Cited by 229
Avet-Loiseau, H., Davies, F. E., Samur, M. K., Corre, J., D'Agostino, M., Kaiser, M. F., Raab, M. S., Weinhold, N., Gutierrez, N. C., Paiva, B., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-01893 · Cited by 192
Approved CAR-T therapies have reproducible efficacy and safety in clinical practice
Vera, D. G., Waghela, H., Nuh, M., Pan, J. Z., & Lulla, P. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2378543 · Cited by 97
Bone Disease in Multiple Myeloma: Biologic and Clinical Implications
Bernstein, Z. S., Kim, E. B., & Raje, N. S. (2022) · Cells · doi:10.3390/cells11152308 · Cited by 97
“In MM specifically, bone-disease-related lesions are the second-mostprevalent CRAB feature [19].”
BackgroundAbduh, M. S. (2023) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2023.103920 · Cited by 82
“From 2013 to 2017, the mortality rate fell from 3.3/ 100,000 to 3.2/100,000 for all age groups and from 21.7/100,000 to 20.5/100,000 for age groups over 65, as reported by the SEER project (Padala et al., 2021; Turesson et al., 2018).”
BackgroundInfluentialPatient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?
Kegyes, D., Constantinescu, C., Vrancken, L., Rasche, L., Gregoire, C., Tigu, B., Gulei, D., Dima, D., Tanase, A., Einsele, H., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01296-2 · Cited by 62
“[1] Due to the aging population, its global burden is constantly rising, with the highest incidence reported in Australia, Western Europe, and the USA.”
BackgroundPu, J., Liu, T., Wang, X., Sharma, A., Schmidt‐Wolf, I. G. H., Jiang, L., & Hou, J. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00507-5 · Cited by 69
“MM is most prevalent in industrialized countries, particularly in Australia, Western Europe, and the United States, where it has the greatest prevalence [2].”
BackgroundTargeting Chemokine Receptor CCR1 as a Potential Therapeutic Approach for Multiple Myeloma
Gilchrist, A., & Echeverria, S. L. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.846310 · Cited by 50
“MM occurs at a slightly higher frequency in men than in women and suggested underlying factors include discrepancies in health-risk behaviors, such as smoking, alcohol consumption, and obesity among men (6).”
BackgroundXian, M., Wang, Q., Xiao, L., Zhong, L., Xiong, W., Ye, L., Pan, S., Zhang, C., Li, Y., Orlowski, R. Z., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50073-x · Cited by 49
“Interestingly, abnormally high levels of serum B2M were detected in most MM patients and thus are considered a biomarker for staging and prognosis of MM 18 ; nevertheless, the role of LILRB1 in MM has been poorly studied.”
Multiple myeloma incidence and mortality trends in the United States, 1999–2020
Zhu, D. T., Park, A., Lai, A., Zhang, L., Attar, H., & Rebbeck, T. R. (2024) · Scientific Reports · doi:10.1038/s41598-024-65590-4 · Cited by 55
“…drive MM screening, this study aims to (1) comprehensively describe geospatial and temporal trends in MM incidence and mortality over the past two decades, and (2) identify racial and ethnic disparities in MM incidence and mortality by population-level sociodemographic and spatial characteristics.”
BackgroundResultInfluentialZhuge, L., Lin, X., Fan, Z., Jia, M., Lin, C., Zhu, M., Teng, H., & Chen, G. (2025) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1527198 · Cited by 49
Structure and function of therapeutic antibodies approved by the US FDA in 2023
Strohl, W. R. (2024) · Antibody Therapeutics · doi:10.1093/abt/tbae007 · Cited by 50
“MM cells produce what is known as M proteins, monoclonal antibodies or fragments thereof that have no specific function [144].”
BackgroundInfluentialAutologous Stem Cell Transplantation in Multiple Myeloma: Where Are We and Where Do We Want to Go?
Morè, S., Corvatta, L., Manieri, V. M., Saraceni, F., Scortechini, I., Mancini, G., Fiorentini, A., Olivieri, A., & Offidani, M. (2022) · Cells · doi:10.3390/cells11040606 · Cited by 44
“Median age at diagnosis is 69 years, and about 65% of patients with newly diagnosed MM (NDMM) are between 45 and 74 years old [1].”
BackgroundNovellis, D. D., Fontana, R., Giudice, V., Serio, B., & Selleri, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010645 · Cited by 36
“Multiple myeloma (MM) is a common hematological malignancy caused by the clonal proliferation of plasma cells (PCs) with a hyperproduction of monoclonal proteins (M-protein) that accumulate in the tissues and lead to organ damage [2].”
BackgroundA population-based study on incidence trends of myeloma in the United States over 2000–2020
Mousavi, S. E., Ilaghi, M., Aslani, A., Yekta, Z., & Nejadghaderi, S. A. (2023) · Scientific Reports · doi:10.1038/s41598-023-47906-y · Cited by 32
García-Sánchez, D., González-González, A., Alfonso-Fernández, A., Del Dujo-Gutiérrez, M., & Pérez-Campo, F. M. (2023) · World Journal of Stem Cells · doi:10.4252/wjsc.v15.i5.421 · Cited by 32
Pilcher, W., Yao, L., Gonzalez‐Kozlova, E., Pita-Juárez, Y. H., Karagkouni, D., Acharya, C. R., Michaud, M. E., Hamilton, M., Nanda, S., Song, Y., et al. (2026) · Nature Cancer · doi:10.1038/s43018-025-01072-4 · Cited by 53
“Multiple myeloma (MM) is the second most prevalent hematological cancer and its incidence continues to rise globally 1,2 .”
Interpretations of the Role of Plasma Albumin in Prognostic Indices: A Literature Review
Gradel, K. O. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12196132 · Cited by 36
Immunotherapy of Multiple Myeloma: Current Status as Prologue to the Future
Abramson, H. N. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242115674 · Cited by 24
“The median age at diagnosis in the U.S. is 69 [3].”
BackgroundCardiovascular complications of modern multiple myeloma therapy: A pharmacovigilance study
Al‐Yafeai, Z., Ananthaneni, A., Ghoweba, M., Abduljabar, H., Aziz, D. J., & Grewal, U. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15499 · Cited by 23
“2 per 100 000 population.(3) While the initial therapy before newer therapeutic advances has classically consisted of VRd (bortezomib + lenalidomide + dexamethasone) and/or stem cell transplant with bortezomib/ Received: 27 May 2022 Revised: 28 July 2022 Accepted: 8 August 2022”
BackgroundMol, I., Hu, Y., LeBlanc, T. W., Cappelleri, J. C., Chu, H., Nador, G., Aydin, D., Schepart, A., & Hlavacek, P. (2024) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2024.2313628 · Cited by 24
“Patients with MM often require multiple lines of sequential therapy, typically involving three main classes of therapy: proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), and anti-CD38 monoclonal antibodies [2–6].”
BackgroundChimeric antigen receptor T-cell therapy for multiple myeloma
Wang, Z., Chen, C., Wang, L., Jia, Y., & Qin, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1050522 · Cited by 24
“MM is the second most common hematological malignancy with an estimated 32270 new cases and 12830 deaths in the United States in 2020 (3).”
BackgroundLi, M., Guo, Q., Shi, Q., Rao, Y., Dong, Y., Chen, F., & Qi, X. (2023) · Discover Oncology · doi:10.1007/s12672-023-00786-0 · Cited by 20
Zhang, D., Zhan, D., Zhang, R., Sun, Y., Duan, C., Yang, J., Jia, W. P., Li, X., Lu, Y., & Lai, X. (2024) · Scientific Reports · doi:10.1038/s41598-024-62298-3 · Cited by 23
Recent Advances in the Applications of Small Molecules in the Treatment of Multiple Myeloma
Abramson, H. N. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032645 · Cited by 21
Iula, R., Novellis, D. D., Trastulli, F., Pepa, R. D., Fontana, R., Carobene, A., Perna, M. D., d’Ambrosio, A., Romano, M., Leone, A., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1026251 · Cited by 17
“Therefore, in most cases, patients are not eligible for hematopoietic stem cell transplantation (HSCT), and alternative therapeutic strategies are considered (1).”
BackgroundInfluentialDu, Z., Zhu, S., Zhang, X., Gong, Z., & Wang, S. (2023) · Cancers · doi:10.3390/cancers15030567 · Cited by 18
“2/100,000 in 2017, likely due to the advancement of the therapeutical armamentarium and increased survival [4].”
BackgroundVitamin D and Multiple Myeloma: A Scoping Review
Mirhosseini, N. Z., Psihogios, A., McLaren, M. D., & Seely, D. (2023) · Current Oncology · doi:10.3390/curroncol30030248 · Cited by 20
“Non-modifiable risk factors in the development of MM include age, sex, race, and family history [2].”
BackgroundInfluentialCosta, T. A., Felix, N. S., Costa, B. A., Godoi, A., Nogueira, A., & Rossi, A. (2023) · British Journal of Haematology · doi:10.1111/bjh.19017 · Cited by 19
Karimi, F., Aghaei, M., & Saki, N. (2025) · Current Treatment Options in Oncology · doi:10.1007/s11864-025-01295-8 · Cited by 18
“In the United States, MM represents approximately 2% of all cancer diagnoses and constitutes around 10% of hematological malignancies; notably, the incidence rates have escalated by 40% within the United States and nearly 130% on a global scale since the year 1990 [4].”
The role of the bone microenvironment in regulating myeloma residual disease and treatment
Dadzie, T. G., & Green, A. C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.999939 · Cited by 16
“also referred to as the CRAB criteria (2).”
BackgroundDebnath, A., Mazumder, R., Mazumder, A., Singh, R. K., & Srivastava, S. (2023) · Letters in Drug Design & Discovery · doi:10.2174/1570180820666230125102954 · Cited by 19
Antibody-drug conjugates, bispecific antibodies and CAR-T cells therapy in multiple myeloma
Tacchetti, P., Talarico, M., Barbato, S., Pantani, L., Mancuso, K., Rizzello, I., Zamagni, E., & Cavo, M. (2024) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2024.2344647 · Cited by 19
“It accounts for 0.9% of all cancers and 10% of hematologic malignancies [1].”
BackgroundInfluentialLuo, Q., Jenkin, D., Weber, M. F., et al. (2024) · The Medical Journal of Australia · doi:10.5694/mja2.52366 · Cited by 16
Instance Segmentation of Multiple Myeloma Cells Using Deep-Wise Data Augmentation and Mask R-CNN
Paing, M. P., Sento, A., Bui, T., et al. (2022) · Entropy · doi:10.3390/e24010134 · Cited by 16
“In healthy conditions, plasma cells produce antibodies called “immunoglobulin” to fight against infections and diseases [2].”
BackgroundDiao, X., Ben, T., Cheng, S., Niu, S., Gao, L., & Xia, N. (2025) · BMC Public Health · doi:10.1186/s12889-025-22240-2 · Cited by 21
“MM prevalence is particularly high among first-degree relatives [21, 22].”
Wiegand, T. L. T., Jung, L., Gudera, J. A., Schuhmacher, L. S., Moehrle, P., Rischewski, J., Mehrzad, P., Jeong, S., Nguyen, L. H., Poeschla, M., et al. (2025) · npj Digital Medicine · doi:10.1038/s41746-025-01817-6 · Cited by 22
“…Diseases predominantly affecting children 42,43 , diseases predominantly affecting adults 44,45 , diseases predominantly affecting elderly 46,47,63,64 , diseases predominantly affecting males 48,49,65,66 , diseases predominantly affecting females 50,51,65,67 , diseases predominantly…”
Jagannath, S., Joseph, N., He, J., Crivera, C., Fu, A. Z., Garrett, A., & Shah, N. D. (2022) · Oncology and Therapy · doi:10.1007/s40487-022-00198-0 · Cited by 14
“Over the past few decades, the 5-year survival rate of MM patients has more than doubled [4, 5].”
BackgroundDuminuco, A., Romano, A., Leotta, D., Spina, E. L., Cambria, D., Bulla, A., Fabro, V. D., Tibullo, D., Giallongo, C., Palumbo, G. A., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1157610 · Cited by 15
Unraveling Obesity and Multiple Myeloma: Insights from Epidemiology and Molecular Mechanisms
Manna, L., Gelsomino, L., Martino, E. A., Gentile, M., Andò, S., Bonofiglio, D., Giordano, C., Catalano, S., & Barone, I. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00644-w · Cited by 19
“MM represents a multifactorial disease, encompassing several risk factors spanning different aspects of life [14].”
Ghanem, B., & Shi, L. (2022) · BioDrugs · doi:10.1007/s40259-022-00557-3 · Cited by 15
“incidence rate of MM in the USA is about seven cases per 100,000 [19].”
BackgroundMol, I., Hu, Y., LeBlanc, T. W., Cappelleri, J. C., Chu, H., Nador, G., Aydin, D., Schepart, A., & Hlavacek, P. (2023) · Current Medical Research and Opinion · doi:10.1080/03007995.2023.2277850 · Cited by 15
Findlay, S., Nair, R., Merrill, R. A., Kaiser, Z., Cajelot, A., Aryanpour, Z., Heath, J., St‐Louis, C., Papadopoli, D. J., Topisirović, I., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022008345 · Cited by 13
Alzaidy, A. H., Ganduh, S. H., Abed, M. J., Dawi, E. A., Jasim, L. S., & Ashoub, M. H. (2025) · Scientific Reports · doi:10.1038/s41598-025-11532-7 · Cited by 19
Ocular complications of plasma cell dyscrasias
Singh, R. B., Singhal, S., Sinha, S., Cho, J., Nguyen, A. X.-L., Dhingra, L. S., Kaur, S., Sharma, V., & Agarwal, A. K. (2023) · European Journal of Ophthalmology · doi:10.1177/11206721231155974 · Cited by 20
“Although, the etiology of plasma cell disorders is not fully elucidated yet, they are characterized by an excessive proliferation of one clone of plasma cells, leading to an increase in the serum level of the clone’s product, the monoclonal immunoglobulin protein (M-protein).(4) M-proteins consist of either one type o…”
Chili, L. H., Mackraj, I., & Rapiti, N. (2023) · PLoS ONE · doi:10.1371/journal.pone.0287304 · Cited by 13
“Studies to confirm improved overall survival where complete remission is achieved in the first year of therapy and those that follow patients for longer periods suggest that survival of up to ten years is achievable [58, 64, 65].”
Bispecific Antibodies for the Management of Relapsed/Refractory Multiple Myeloma
Tacchetti, P., Barbato, S., Mancuso, K., Zamagni, E., & Cavo, M. (2024) · Cancers · doi:10.3390/cancers16132337 · Cited by 22
“It is characterized by the clonal proliferation of plasma cells (PCs), production of monoclonal protein biomarkers, and possible organ dysfunction [1].”
BackgroundŁuczkowska, K., Kulig, P., Baumert, B., & Machaliński, B. (2022) · Nutrients · doi:10.3390/nu14235190 · Cited by 13
Chen, M., Zhu, J., Yang, X., Yao, J., Liu, Y., & Liu, Q. (2022) · European journal of medical research · doi:10.1186/s40001-022-00923-5 · Cited by 13
“As a plasma cell malignancy, MM remains incurable, with 5-year survival about 50% according to different studies [2, 3].”
BackgroundHanssens, H., Meeus, F., Gesquiere, E., Puttemans, J., Vlaeminck, Y. D., Veirman, K. D., Breckpot, K., & Devoogdt, N. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115634 · Cited by 11
“After malignant transformation, these cells produce an excessive amount of a dysfunctional antibody, termed M-protein or paraprotein, which is released into the bloodstream and is, in turn, largely responsible for the renal dysfunction observed in patients [3,4].”
BackgroundAilawadhi, S., Adu, Y., Frank, R. D., Das, S., Hodge, D. O., Fernandez, A., Flott, C., Elliott, J. B., Parrondo, R. D., Sher, T., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01067-x · Cited by 11
“MM remains an incurable disorder, however, over the past two decades therapeutic advancements, as well as increasing utilization of modalities such as stem cell transplant (SCT), has led to improving patient outcomes [1, 3 – 5].”
BackgroundMultiple Myeloma: Improved Outcomes Resulting from a Rapidly Expanding Number of Therapeutic Options
Mettias, S., ElSayed, A., Moore, J., & Berenson, J. R. (2025) · Targeted Oncology · doi:10.1007/s11523-024-01122-4 · Cited by 15
Adegbite, B. O., Tan, C. R. C., Shekarkhand, T., Firestone, R., Jurgens, E. M., Miller, K., Lesokhin, A. M., Shah, G. L., Korde, N., Rajeeve, S., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025015973 · Cited by 16
Garderet, L., Gras, L. A., Köster, L., Baaij, L. G. A., Hamad, N., D’Souza, A., Estrada‐Merly, N., Hari, P., Saber, W., Cowan, A. J., et al. (2024) · American Journal of Hematology · doi:10.1002/ajh.27451 · Cited by 17
Longitudinal Analysis of Patient-Reported Cognitive Function in Multiple Myeloma
Yusuf, A. R. S., Heiling, H., Deal, A. M., Jensen, C. E., Mangieri, N. J., Nyrop, K. A., Lichtman, E. I., Rubinstein, S. M., Grant, S. J., Wood, W. A., et al. (2022) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2022.08.002 · Cited by 11
Neurologic Outcomes After Radiation Therapy for Severe Spinal Cord Compression in Multiple Myeloma
Zijlstra, H., Striano, B. M., Crawford, A. M., et al. (2023) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.22.01335 · Cited by 10
“Due to the diffuse bone loss and hematologic deficiencies associated with MM, postoperative complications and the risk of infection are increased25,26, and the benefits of surgery must be carefully weighed against potential risks on an individual basis.”
BackgroundMethodInfluentialActivated platelet-derived exosomal LRG1 promotes multiple myeloma cell growth
Gao, M., Dong, H., Jiang, S., Chen, F., Fu, Y., & Luo, Y. (2024) · Oncogenesis · doi:10.1038/s41389-024-00522-5 · Cited by 12
“Multiple myeloma (MM), a common hematological malignancy, is characterized by the accumulation of plasma cells in the bone marrow and often induces anemia, osteolytic lesions, renal insuf fi ciency, hypercalcemia, and immunode fi ciency [1].”
BackgroundLiu, L., Liu, L., Liu, R., Liu, J., & Cheng, Q. (2023) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13768 · Cited by 10
“Multiple myeloma (MM) is a kind of haematological malignancy that is characterised by renal insufficiency, anaemia, bone destruction and hypercalcaemia.(1,2) About 20%–25% of newly diagnosed and 50% of relapsed MM patients have different degrees of renal insufficiency,(3) and most MM patients combined with renal insuf…”
BackgroundSanz-Solas, A., Labrador, J., Alcaraz, R., Cuevas, B., Campo, R. V., Cuevas, M. V., & Saiz‐Rodríguez, M. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13040695 · Cited by 11
“MM is an adult neoplasm with a median diagnosis age of 69 years old, with its incidence being higher in men [6].”
BackgroundHead-to-Head Comparison between FDG and 11C-Methionine in Multiple Myeloma: A Systematic Review
Filippi, L., Frantellizzi, V., Bartoletti, P., VINCENTIS, G. D., Schillaci, O., & Evangelista, L. (2023) · Diagnostics · doi:10.3390/diagnostics13122009 · Cited by 12
“The second is the activation of skeletal osteoclasts through the nuclear factor kappa-B ligand (RANKL), leading to the formation of lytic lesions and, as a further step, the appearance of pain, fractures and hypercalcemia [1,2].”
BackgroundGood Cop, Bad Cop: Profiling the Immune Landscape in Multiple Myeloma
Sharma, N., & Choudhary, B. (2023) · Biomolecules · doi:10.3390/biom13111629 · Cited by 11
“…can establish multiple myeloma (MM) precursor conditions such as monoclonal gammopathy of uncertain significance (MGUS) and smoldering MM (SMM) [5,7–9]. uncertain significance (MGUS) and smoldering MM (SMM) [5,7–9]. multiple myeloma (MM) precursor conditions such as monoclonal gammopathy of Figure…”
InfluentialPereira, R., & Bergantim, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094996 · Cited by 12
“Notably, it is experiencing an increase in incidence and prevalence in the developed world [2–4].”
BackgroundA systematic review on the epidemiology and treatment options of multiple Myeloma in Asia
Chng, W. J., Nagarajan, C., Huang, S., Malhotra, P., Hwang, Y., Blunk, V., Singh, M., & Wang, L. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e39698 · Cited by 14
Wang, X., Cheng, L., Liu, A., Liu, L., Gong, L., & Shen, G. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-024-05848-7 · Cited by 9
Yu, M., Zhang, J., Fu, J., Li, S., & Cui, X. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.156627 · Cited by 9
Derman, B. A., Tan, C. R. C., Steinfield, I., Wilson, F. R., Lin, D., Wu, B., Fernandez, M., Fowler, J., Paner-Straseviciute, A., Kim, N., et al. (2025) · Cancers · doi:10.3390/cancers17071235 · Cited by 9
“While 5-year survival rates of MM have more than doubled since the 1970s to a rate of 61.1% [1,2], the disease is typically characterized by a series of responses and relapses meaning patients ultimately require multiple lines of therapy [3].”
InfluentialPlano, F., Corsale, A. M., Gigliotta, E., Camarda, G. M., Vullo, C., Simone, M. D., Azgomi, M. S., Speciale, M., Carlisi, M., Caccamo, N., et al. (2023) · Hematology Reports · doi:10.3390/hematolrep15010004 · Cited by 12
Association between dexamethasone exposure and visually significant cataracts in multiple myeloma
Banerjee, R. K., Martínez, J. A. H., Pérez, P. A. F., et al. (2023) · American Journal of Hematology · doi:10.1002/ajh.27133 · Cited by 9
Bone marrow adipocytes provide early sign for progression from MGUS to multiple myeloma
El-Masri, B. M., Leka, B., Mustapha, F., Gundesen, M. T., Hinge, M., Lund, T., Andersen, T. L., Diaz‐delCastillo, M., & Jafari, A. (2024) · Oncotarget · doi:10.18632/oncotarget.28548 · Cited by 12
Abraham, E., Trainor, N., Ostrout, N., & Hewitt, M. M. (2021) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2021.100340 · Cited by 11
18F-FDG Versus Non-FDG PET Tracers in Multiple Myeloma
Hemrom, A., Tupalli, A., Alavi, A. A., & Kumar, R. (2022) · PET Clinics · doi:10.1016/j.cpet.2022.03.001 · Cited by 9
The diagnostic and prognostic value of haematologic parameters in multiple myeloma patients
Han, F., Sheng, N., Sheng, C., & Meng, J. (2023) · Hematology · doi:10.1080/16078454.2023.2240145 · Cited by 9
“It is characterized by the accumulation of malignant plasma cells in the bone marrow, leading to anaemia, bone pain, renal impairment, hypercalcemia, and infection[2].”
BackgroundMartino, M. V., Gamberi, B., Antonioli, E., Aquino, S., Pepa, R. D., Malerba, L., Mangiacavalli, S., Pezzatti, S., Bringhen, S., & Zamagni, E. (2024) · Expert Review of Hematology · doi:10.1080/17474086.2024.2357274 · Cited by 11
“Multiple myeloma (MM) is a clonal plasma cell malignancy accounting for approximately 10% of hematological cancers and 0.9% of all cancers, with an age-standardized incidence of 2.1/100,000 among men and 1.4/100,000 among women [1–3].”
BackgroundInfluentialTrends in Outcomes After Upfront Autologous Transplant for Multiple Myeloma Over Three Decades
Pasvolsky, O., Marcoux, C., Dai, J., Milton, D. R., Tanner, M. R., Syed, N., Bashir, Q., Srour, S. A., Saini, N. Y., Lin, P. Y., et al. (2024) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2024.06.001 · Cited by 13
Vu, T., Wang, Y., Fowler, A., Simieou, A., & McCarty, N. (2024) · Cells · doi:10.3390/cells13171431 · Cited by 9
Novellis, D. D., Derudas, D., Vincelli, D. I., Fontana, R., Pepa, R. D., Palmieri, S., Accardi, F., Rotondo, F., Morelli, E., Gigliotta, E., et al. (2024) · European Journal Of Haematology · doi:10.1111/ejh.14314 · Cited by 9
Selinexor’s Immunomodulatory Impact in Advancing Multiple Myeloma Treatment
Tasbihi, K., & Bruns, H. (2025) · Cells · doi:10.3390/cells14060430 · Cited by 9
“Due to therapeutic innovations, the 5-year overall survival has doubled over the past decade to approximately 54% [28].”
Reviewing the Significance of Vitamin D Substitution in Monoclonal Gammopathies
Innao, V., Allegra, A., Ginaldi, L., Pioggia, G., Martinis, M. D., Musolino, C., & Gangemi, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094922 · Cited by 14
JIANG, W., & Zhou, M. (2024) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2024.043423 · Cited by 8
“hematologic malignancy featured by aberrant bone marrow clonal plasma cell accumulation, diagnosis of plasmacytoma, monoclonal protein in serum or urine, and end-organ injury signs [2 – 4].”
BackgroundAdvancements in the Treatment of Multiple Myeloma
Zavaleta‐Monestel, E., Quesada-Villaseñor, R., Barrantes-López, M., Arguedas‐Chacón, S., Campos-Hernández, J., Rojas-Chinchilla, C., García-Montero, J., Castro-Ulloa, J., Anchía-Alfaro, A., & Montenegro-Chaves, J. R. (2024) · Cureus · doi:10.7759/cureus.74970 · Cited by 12
Plasma Cell Myeloma/Multiple Myeloma
Bahk, W.-J. (2023) · Springer eBooks · doi:10.1007/978-981-99-5498-8_5 · Cited by 8
Jang, B., Jeong, J., Heo, K., Koh, Y., & Lee, J. (2024) · Blood Research · doi:10.1007/s44313-024-00004-y · Cited by 12
“The median age of patients with MM is 69 years, and 69% have preexisting cardiovascular comorbidities at the time of diagnosis [18, 19].”
BackgroundRole of Non-Coding RNAs in Diagnosis, Prediction and Prognosis of Multiple Myeloma
Dubaj, M., Bigosiński, K., Dembowska, A., Mlak, R., Szudy‐Szczyrek, A., Malecka-Massalska, T. J., & Homa‐Mlak, I. (2024) · Cancers · doi:10.3390/cancers16051033 · Cited by 9
“MM is a disease mainly of older people (average age of diagnosis is 69 years); it occurs 1.5 times more often in men than in women and 2 times more often in African-Americans than in Caucasians [3].”
BackgroundInfluentialCurrent Treatment Strategies for Multiple Myeloma at First Relapse
Mavrothalassitis, E., Triantafyllakis, K., Malandrakis, P., Gavriatopoulou, M., Kleber, M., & Ntanasis‐Stathopoulos, I. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14051655 · Cited by 7
Wei, Y., Gao, W., Wang, S., Li, Q., & Xu, S. (2025) · Frontiers in Epidemiology · doi:10.3389/fepid.2025.1568688 · Cited by 13
Epidemiology of monoclonal gammopathy in Morocco – A hospital‐based study
Ouzzif, Z., Doghmi, K., Messaoudi, N., Bouhsain, S., Machtani, S. E., Biaz, A., Rachid, A., Dami, A., Bezza, A., & Maataoui, A. E. (2023) · Cancer Reports · doi:10.1002/cnr2.1814 · Cited by 8
“5 per 100 000), blacks more than whites, thus, the highest prevalence rate is observed in African Americans, particularly in those aged 80–84 years and older.(2) Some mutations and cytogenetic abnormalities are associated with high-risk MM, such as translocations (t(4;14), t(14;16), t(14;20)), deletions: del (17p), ga…”
BackgroundPreclinical and clinical evaluation of the Janus Kinase inhibitor ruxolitinib in multiple myeloma
Dosso, A. D., Tadevosyan, E., & Berenson, J. R. (2024) · Oncotarget · doi:10.18632/oncotarget.28547 · Cited by 9
Osama, M., Khan, M. H., Khan, S., Hussain, A., Tahir, A., Ullah, M., Afridi, A., Ullah, U., & Rehman, W. U. (2025) · Therapeutic Advances in Hematology · doi:10.1177/20406207251314289 · Cited by 8
How Old is Too Old for CAR-T Cell Therapies in Multiple Myeloma?
Rajeeve, S., & Usmani, S. Z. (2023) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2023.05.001 · Cited by 7
Current Status and Future of Artificial Intelligence in MM Imaging: A Systematic Review
Alipour, E., Pooyan, A., Zadeh, F. S., Darbandi, A. D., Bonaffini, P. A., & Chalian, M. (2023) · Diagnostics · doi:10.3390/diagnostics13213372 · Cited by 9
“Five-year survival rates of MM are estimated to be 74.8% and 52.9%, respectively [4].”
BackgroundInfluentialGutiérrez‐González, A., del Hierro, I., & Cariaga-Martínez, A. E. (2024) · Biology · doi:10.3390/biology13110923 · Cited by 11
Biran, N., Dhakal, B., Niesvizky, R., et al. (2025) · British Journal of Haematology · doi:10.1111/bjh.20050 · Cited by 6
The Gut Microbiome Role in Multiple Myeloma: Emerging Insights and Therapeutic Opportunities
George, M. Y., Gamal, N. K., Mansour, D. E., Famurewa, A. C., Bose, D., Messiha, P. A., & Cerchione, C. (2025) · Hematology Reports · doi:10.3390/hematolrep17060056 · Cited by 6
Park, H., Lee, S. Y., Lee, J., Pak, J., Lee, K., Lee, S., & Jung, J. (2022) · Diagnostics · doi:10.3390/diagnostics12040923 · Cited by 7
Kinase Inhibition in Multiple Myeloma: Current Scenario and Clinical Perspectives
Barreto, I. V., Machado, C. B., Almeida, D. B., Pessoa, F. M. C. D. P., Gadelha, R. B., Pantoja, L. D. C., Oliveira, D. D. S., Ribeiro, R. M., Lopes, G. S., de Moraes, M. O., et al. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091784 · Cited by 7
“5 to 1 and being twice as common in African Americans compared to Caucasians [2,10,11].”
BackgroundInfluentialMikulski, D., Robak, P. J., Ryżewska, W., Stańczak, K., Kościelny, K., Góra‐Tybor, J., & Robak, T. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11195908 · Cited by 6
“It is the second most common type of blood cancer in the United States and Europe; frequently develops in people over the age of 60, with the median age at diagnosis being 69 in the US; and is more prevalent in men than women [3,4].”
BackgroundTanaka, M., Yasui, M., & Hara‐Chikuma, M. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.07.053 · Cited by 6
Gerov, V., Gerova, D. I., Micheva, I., Nikolova, M., Pasheva, M. G., Nazifova, N., & Galunska, B. T. (2023) · Cancers · doi:10.3390/cancers15235562 · Cited by 7
“Multiple myeloma (MM) is a plasma cell disorder with increasing incidence world-wide in recent decades [1].”
Metadata
- Authors
- Padala, S. A., Barsouk, A., Barsouk, A., Rawla, P., Vakiti, A., Kolhe, R., Kota, V., & Ajebo, G. H.
- Affiliations
- Augusta University (US)
- Allegheny Health Network (US)
- Sovah Health Martinsville (US)
- Corresponding author
- Padala, Sandeep Anand
- ORCID
- Venue
- Medical Sciences
- Publisher
- MDPI AG
- Published
- 2021-01-20
- Volume
- 9
- Issue
- 1
- Pages
- 3
- ISSN
- 2076-3271 (ISSN-L)
- PMC
- PMC7838784
- OpenAlex
- W3125352349
- Semantic Scholar
- f98f43b63e68b1a4fa37ed1682b10b64d590a291
- Cited by
- 332
- References
- 56
- Citations by year
- 2026: 51 · 2025: 84 · 2024: 87 · 2023: 66 · 2022: 38 · 2021: 5
- FWCI
- 8.58
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Medical Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Keywords
- multiple myeloma, incidence and mortality trends, risk factors, M protein, International Staging System, beta2-microglobulin, lactate dehydrogenase, chromosomal abnormalities, hematopoietic stem cell transplantation, bisphosphonates, skeletal-related events, relapsed multiple myeloma, daratumumab, proteasome inhibitors, immunomodulating agents, CAR T-cell therapy, BCMA, monoclonal gammopathy of undetermined significance, smoldering multiple myeloma
- MeSH terms
- Immunomodulating Agents, Anemia, Humans, Hypercalcemia, Multiple Myeloma, Pain, Paraproteinemias, Renal Insufficiency
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.